Evogene Ltd. (EVGN) stock
Close on Nov 11, 2026Market cap $3.45MP/E 0.4Yield –
Evogene Ltd. saw revenue fall 30.9% to $3.85M over fiscal 2025. Free cash flow was -$13.64M. At the latest close the market valued the company at $3.45M, 0.4 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $3.45M
- P/E ratio
- 0.4
- Price to sales
- 0.89
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -395.60%
Fundamentals
- Revenue
- $3.85M
- Net income
- -$8.49M
- EPS, diluted
- $1.08
- Free cash flow
- -$13.64M
Trading
- Previous close
- $0.37
- Open
- $0.34
- Day's range
- $0.33 – $0.43
- Volume
- 372,129
- Average volume (20 days)
- 569,684
- Beta (5 years)
- 1.04
- 52-week range
- $0.25 – $1.28
- RSI (14 days)
- 53.9
- Volatility (1 year)
- 86.1%
- Relative volume
- 0.24×
- WACC
- 10.1%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | EVGN | S&P 500 | Difference | EVGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +3.5% | -2.4% | +5.9 pts | ||
| 3 months | -43.6% | -1.2% | −42.4 pts | ||
| Year to date | -64.1% | +12.3% | −76.3 pts | ||
| 1 year | -68.1% | +12.4% | −80.6 pts | ||
| 3 years | -93.1% | +78.8% | −171.9 pts | -58.9% | +21.4% |
| 5 years | -98.4% | +75.2% | −173.6 pts | -56.5% | +11.9% |
| 10 years | -99.3% | +311.1% | −410.4 pts | -39.4% | +15.2% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Evogene filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Evogene
Agricultural Chemicals
Evogene Ltd. is a computational biology company that develops products for life science markets. The company operates through specialized subsidiaries focused on agriculture, human health, and industrial applications, including AgPlenus, Biomica, Casterra Ag, and Lavie Bio. Evogene's offerings encompass agricultural biologicals, microbiome-based therapeutics, ag-chemicals, and castor seed solutions, addressing the needs of agricultural producers, industrial partners, and healthcare entities.
Company profile, executives and historyEvogene stock: common questions
What is Evogene's stock price?
EVGN closed at $0.40 on Nov 11, 2026, up 6.29% on the day. Over the past 52 weeks it traded between $0.25 and $1.28.
What is Evogene's market cap?
Evogene was worth $3.45M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is EVGN's P/E ratio?
EVGN trades at 0.4 times earnings, based on diluted earnings per share of $1.08 over fiscal 2025.
How much revenue does Evogene make?
Evogene reported revenue of $3.85M for fiscal 2025, down 30.9% from a year earlier.
Does Evogene pay a dividend?
No. Evogene has not paid a cash dividend over the last twelve months.
How has EVGN stock performed over the past year?
Including dividends, EVGN returned -68.1% over the past year, against +12.4% for the S&P 500.
How many EVGN shares are sold short?
0M shares were sold short at the latest FINRA report, 1.64% of the float, or 2.3 days of average trading volume.
Who are Evogene's competitors?
Companies most similar to Evogene by business, industry and size include CBUS, SNES, DYAI, PRPH, PTCHF.
See a number that looks wrong?